Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Napo said in the notice on the U.S. Health

Read More »

News Alert: Key House Committee Excludes “Spread Pricing” Language that 340B Entities Feared from Drug Pricing Legislation

The House Energy & Commerce Committee excluded spread-pricing language that 340B entities feared from forthcoming drug pricing legislation.

340B covered entities are breathing easier today upon learning that U.S. House Democrats excluded much-feared Medicaid managed care “spread pricing” language from forthcoming drug pricing legislation.

The House Energy & Commerce Committee late yesterday released the text of the 16

Read More »

In Largely Symbolic Move, Becerra Expresses “Strong Support” for 340B in Drug Pricing Plan

HHS Secretary Xavier Becerra yesterday expressed "strong support" for the 340B program in a drug pricing report to the White House, but recommended no changes to the program.

U.S. Health and Human Services Secretary Xavier Becerra yesterday reiterated HHS’ “strong support for the 340B Drug Pricing Program” in a 29-page plan to lower drug prices.

Becerra’s Sept. 9 report to White House domestic and economic policy counselors

Read More »

N.C. Lawmakers Leave 340B DSH, Children’s, and Cancer Hospitals and HTCs Unprotected from PBM Pickpocketing

Hospital sign
North Carolina lawmakers excluded 340B disproportionate share hospitals, children’s hospitals, free-standing cancer hospitals, and hemophilia treatment centers from protection against discriminatory PBM treatment under a bill passed and sent to the governor this week.

North Carolina lawmakers approved a final deal Wednesday to protect some, but not all, of the state’s 340B covered entities against discrimination by pharmacy benefit managers (PBMs).

Under an agreement a House-Senate conference committee reached on Sept. 8, 340B

Read More »

340B Report Publisher and CEO: Congress Needs to Intervene to Resolve Contract Pharmacy Impasse

340B Report Publisher and CEO Ted Slafsky addresses enforcement actions and litigation surrounding state 340B contract pharmacy laws in his latest column.

The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

Urging

Read More »

340B Hospitals Provide Almost $68 Billion Annually in Community Benefits, AHA Says

340B hospitals provided $67.9 billion in total community benefits in 2018, AHA reported yesterday.

Hospitals participating in the 340B program provided $67.9 billion in total benefits to their communities in 2018, the American Hospital Association (AHA) reported yesterday. Community benefits represented 13.7% of total 340B hospital expenses, the group said.

AHA broke out

Read More »

HRSA Grants 340B Flexibilities to N.J. and N.Y. Due to Hurricane

Federal health officials yesterday added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.

Federal health officials have added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.

The U.S. Health Resources and Services Administration (HRSA) posted the notice about the East Coast states’ addition

Read More »

Providers Concerned About Drug Pricing Reform’s Potential to Undermine 340B

340B covered entities are telling Congress that while they support federal action to lower drug prices, they worry that changes could weaken the 340B program and the wider health care safety net.

340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.

Entities are telling key members of Congress and their staffs that while they support federal action to

Read More »

340B Hospitals Make Their Case to Supreme Court for Ending Deep Medicare Drug Payment Cuts

Hospital groups filed a brief with the U.S. Supreme Court on Friday in their lawsuit challenging the deep cut in 340B hospitals' Medicare Part B drug reimbursement.

Federal health officials “violated unambiguous statutory commands” in 2018 when they lowered lower Medicare Part B drug reimbursement rates for 340B hospitals by nearly 30% and their decision should be set aside, hospital groups and individual hospitals told the U.S.

Read More »

Hearing Friday on PhRMA’s Push to Quash First State Law to Protect 340B Contract Pharmacy Program

Arkansas Insurance Commissioner Alan McClain temporarily suspended his state's new 340B contract pharmacy law pending a review of its constitutionality.

The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report